First published 9/28/2026, 8:22:15 AM · Last updated 9/28/2026, 8:22:15 AM

Construction and validation of patient-derived explant model for idiopathic pulmonary fibrosis: antifibrotic and therapeutic potential of a novel thiosemicarbazone derivative and its platinum complex

Journal article reporting the construction and validation of a patient-derived explant model for idiopathic pulmonary fibrosis and testing a novel thiosemicarbazone derivative and its platinum complex for antifibrotic and therapeutic potential. The excerpt provides no location or implementation details beyond publication metadata.

Categories: science-and-space, public-health, positive-progress

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 4/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

It describes a new preclinical model and reports antifibrotic therapeutic potential of a novel compound for idiopathic pulmonary fibrosis.

Sources

Construction and validation of patient-derived explant model for idiopathic pulmonary fibrosis: antifibrotic and therapeutic potential of a novel thiosemicarbazone derivative and its platinum complex

Report an issue